Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/8491
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Acar, Göksemin | - |
dc.contributor.author | Tanriöver, G. | - |
dc.contributor.author | Demir, R. | - |
dc.date.accessioned | 2019-08-16T12:41:14Z | - |
dc.date.available | 2019-08-16T12:41:14Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0161-6412 | - |
dc.identifier.uri | https://hdl.handle.net/11499/8491 | - |
dc.identifier.uri | https://doi.org/10.1179/1743132812Y.0000000068 | - |
dc.description.abstract | Angiogenesis, recruitment of new blood vessels, is an essential component of the metastatic pathway. These vessels provide the principal route by which tumor cells exit the primary tumor site and enter the circulation. For many tumors, the vascular density can provide a prognostic indicator of metastatic potential, with the highly vascular primary tumors having a higher incidence of metastasis than poorly vascular tumors. The discovery and characterization of tumor-derived angiogenesis modulators greatly contributed to our understanding of how tumors regulate angiogenesis. However, although angiogenesis appears to be a rate-limiting event in tumor growth and metastatic dissemination, a direct connection between the induction of angiogenesis and the progression to tumor malignancy is less well understood. In this review, we discuss the observations concerning the modulation of angiogenesis and their implications in various neurological disorders, as well as their potential impact on cancer therapy. © W. S. Maney & Son Ltd 2012. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Neurological Research | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Angiogenesis | en_US |
dc.subject | Anti-angiogenic therapies | en_US |
dc.subject | Neurological disorders | en_US |
dc.subject | Tumor metastasis | en_US |
dc.subject | angiogenesis inhibitor | en_US |
dc.subject | angiotensin II | en_US |
dc.subject | bevacizumab | en_US |
dc.subject | camptothecin | en_US |
dc.subject | cediranib | en_US |
dc.subject | cyclophosphamide | en_US |
dc.subject | erlotinib | en_US |
dc.subject | gefitinib | en_US |
dc.subject | gelatinase A | en_US |
dc.subject | gelatinase B | en_US |
dc.subject | imatinib | en_US |
dc.subject | lomustine | en_US |
dc.subject | nevaxar | en_US |
dc.subject | scatter factor | en_US |
dc.subject | sorafenib | en_US |
dc.subject | thrombospondin 1 | en_US |
dc.subject | unclassified drug | en_US |
dc.subject | vasculotropin | en_US |
dc.subject | vatalanib | en_US |
dc.subject | angiogenesis | en_US |
dc.subject | antiangiogenic activity | en_US |
dc.subject | arteriovenous malformation | en_US |
dc.subject | blood brain barrier | en_US |
dc.subject | brain blood vessel | en_US |
dc.subject | brain disease | en_US |
dc.subject | brain metastasis | en_US |
dc.subject | cancer chemotherapy | en_US |
dc.subject | cancer growth | en_US |
dc.subject | cancer prognosis | en_US |
dc.subject | cell proliferation | en_US |
dc.subject | competitive inhibition | en_US |
dc.subject | down regulation | en_US |
dc.subject | drug efficacy | en_US |
dc.subject | glioblastoma | en_US |
dc.subject | hemangioblastoma | en_US |
dc.subject | hereditary hemorrhagic telengiectasia | en_US |
dc.subject | histopathology | en_US |
dc.subject | human | en_US |
dc.subject | hypertension | en_US |
dc.subject | hypoxemia | en_US |
dc.subject | macrophage | en_US |
dc.subject | maximum tolerated dose | en_US |
dc.subject | meningioma | en_US |
dc.subject | neurologic disease | en_US |
dc.subject | overall survival | en_US |
dc.subject | progression free survival | en_US |
dc.subject | protein expression | en_US |
dc.subject | protein secretion | en_US |
dc.subject | review | en_US |
dc.subject | signal transduction | en_US |
dc.subject | thrombocytopenia | en_US |
dc.subject | tumor cell | en_US |
dc.subject | tumor localization | en_US |
dc.subject | tumor vascularization | en_US |
dc.subject | upregulation | en_US |
dc.subject | vascular tumor | en_US |
dc.subject | Angiogenesis Inhibitors | en_US |
dc.subject | Animals | en_US |
dc.subject | Brain Neoplasms | en_US |
dc.subject | Humans | en_US |
dc.subject | Neovascularization, Pathologic | en_US |
dc.subject | Nervous System Diseases | en_US |
dc.title | Angiogenesis in neurological disorders: A review | en_US |
dc.type | Review | en_US |
dc.identifier.volume | 34 | en_US |
dc.identifier.issue | 7 | en_US |
dc.identifier.startpage | 627 | - |
dc.identifier.startpage | 627 | en_US |
dc.identifier.endpage | 635 | en_US |
dc.authorid | 0000-0001-8068-9060 | - |
dc.identifier.doi | 10.1179/1743132812Y.0000000068 | - |
dc.relation.publicationcategory | Diğer | en_US |
dc.identifier.pmid | 22889669 | en_US |
dc.identifier.scopus | 2-s2.0-84865140991 | en_US |
dc.identifier.wos | WOS:000307532500001 | en_US |
dc.identifier.scopusquality | Q2 | - |
dc.owner | Pamukkale University | - |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Review | - |
item.grantfulltext | none | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
CORE Recommender
SCOPUSTM
Citations
3
checked on Nov 16, 2024
WEB OF SCIENCETM
Citations
3
checked on Nov 21, 2024
Page view(s)
34
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.